Related Experiment Videos
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication
Insights
Ticlopidine, an antiplatelet drug, significantly inhibited platelet aggregation in men with intermittent claudication. However, it did not improve walking ability or blood flow, suggesting it was insufficient for extensive atherosclerosis.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Vascular Biology
Background:
- Atherosclerotic intermittent claudication is characterized by impaired walking ability due to reduced blood flow.
- Haemorheological abnormalities, including coagulation and fibrinolysis issues, contribute to the prothrombotic state in atherosclerosis.
Purpose of the Study:
- To evaluate the efficacy of Ticlopidine, a novel antiplatelet agent, in improving clinical outcomes and haemorheological parameters in patients with atherosclerotic intermittent claudication.
Main Methods:
- A one-year, double-blind, randomized trial involving 51 men with atherosclerotic intermittent claudication.
- Daily administration of Ticlopidine (500 mg/day) to assess its impact on platelet aggregation and other haemorheological factors.
Main Results:
- Ticlopidine demonstrated significant inhibition of platelet aggregation over 12 months.
- No significant improvements were observed in walking ability, Doppler ankle-pressure indices, or calf blood flow.
- Abnormalities in coagulation, viscosity, and fibrinolysis were not fully corrected by Ticlopidine treatment.
Conclusions:
- Sustained platelet inhibition with Ticlopidine for one year was insufficient to overcome the prothrombotic nature of extensive atherosclerosis.
- Ticlopidine did not provide significant clinical benefit for patients suffering from atherosclerotic intermittent claudication.
Abstract:
Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent. Ticlopidine caused significant inhibition of platelet aggregation but did not fully correct abnormalities of coagulation, viscosity, and fibrinolysis. There was no significant improvement in walking ability, Doppler ankle-pressure indices, or calf blood flow. Sustained platelet inhibition for 12 months was insufficient to correct the prothrombotic abnormality of extensive atherosclerosis.